Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Feb 1;209(3):239-241.
doi: 10.1164/rccm.202311-2159ED.

Questions and Answers? Depression Symptoms Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment for Cystic Fibrosis

Tim W R Lee  1 , Alistair J A Duff  2   3
Affiliations
Editorial

Questions and Answers? Depression Symptoms Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment for Cystic Fibrosis

Tim W R Lee et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Effects of ELX/TEZ/IVA on symptoms of depression measured by Patient Health Questionnaire-9 (PHQ-9) score, measured at baseline and at 8–16 weeks after the initiation of ELX/TEZ/IVA in 70 adults with cystic fibrosis. (A) Paired individual PHQ-9 scores. Solid lines represent the group median and dashed lines represent 25th and 75th percentile. (B) Alluvial graphic showing the flow of individuals’ PHQ-9 scores among minimal, mild, moderate, and severe depression symptom categories, demonstrating that a proportion of individuals had worse PHQ-9 scores with ELX/TEZ/IVA therapy. **Denotes P < 0.01 compared with baseline. Reprinted by permission from Reference . ELX = elexacaftor; ETI = elexacaftor/tezacaftor/ivacaftor; IVA = ivacaftor; TEZ = tezacaftor.
See this image and copyright information in PMC

Comment in

Comment on

  • Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
    Ramsey B, Correll CU, DeMaso DR, McKone E, Tullis E, Taylor-Cousar JL, Chu C, Volkova N, Ahluwalia N, Waltz D, Tian S, Mall MA. Ramsey B, et al. Am J Respir Crit Care Med. 2024 Feb 1;209(3):299-306. doi: 10.1164/rccm.202308-1525OC. Am J Respir Crit Care Med. 2024. PMID: 37890129 Free PMC article. Review.

References

    1. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. VX17-445-103 Trial Group Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutaton: a double-blind, randomised, phase 3 trial. Lancet . 2019;394:1940–1948. - PMC - PubMed
    1. Lopez A, Daly C, Vega-Hernandez G, MacGregor G, Rubin JL. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J Cyst Fibros . 2023;22:607–614. - PubMed
    1. Tindell W, Su A, Oros SM, Rayapati AO, Rakesh G. Trikafta and psychopathology in cystic fibrosis: a case report. Psychosomatics . 2020;61:735–738. - PubMed
    1. Heo S, Young DC, Safirstein J, Bourque B, Antell MH, Diloreto S, et al. Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy. J Cyst Fibros . 2022;21:339–343. - PubMed
    1. Arslan M, Chalmers S, Rentfrow K, Olson JM, Dean V, Wylam ME, et al. Suicide attempts in adolescents with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy. J Cyst Fibros. 2023;22:427–430. - PubMed